Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31273984 | 1.00 | MEN1 (0.38) | MEN1KMT2ALMNACA2CHRM2 | |
| SCHEMBL3434112 | 1.00 | MEN1 (0.38) | MEN1KMT2ALMNACA2CHRM2 | |
| SCHEMBL15948910 | 0.85 | CHRM2 (0.46) | MEN1KMT2ALMNACA2CHRM2 | |
| SCHEMBL15301330 | 0.76 | MEN1 (0.37) | MEN1KMT2ALMNACHRM2CHRM4 | |
| SCHEMBL3898973 | 0.75 | ALDH1A1 (0.34) | MEN1KMT2ALMNACA2ALDH1A1 | |
| SCHEMBL10813862 | 0.74 | MEN1 (0.36) | MEN1KMT2ALMNA | |
| SCHEMBL12021714 | 0.73 | SLC6A2 (0.35) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL10368095 | 0.72 | MEN1 (0.33) | MEN1KMT2ALMNACA2 | |
| SCHEMBL4510179 | 0.71 | JAK2 (0.39) | MEN1KMT2ACHRM2CHRM4CHRM5 | |
| SCHEMBL10041484 | 0.71 | CA1 (0.43) | MEN1KMT2ALMNACA2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4463457-B1 | PYRROLO[1,2-B]-2-PYRIDAZINONE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LTD (IN) | 2026-02-04 | — | — | EP | disclosed |
| US-12275746-B2 | Pyrrolo[1,2-b]-2-pyridazinone compounds as 5-HT4 receptor agonists | SUVEN LIFE SCIENCES LIMITED (IN) | 2025-04-15 | — | — | US | disclosed |
| US-20250019386-A1 | PYRROLO[1,2-b]-2-PYRIDAZINONE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2025-01-16 | — | — | US | disclosed |
| US-9873692-B2 | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170334901-A1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-11-23 | — | — | US | disclosed |
| US-9630960-B2 | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-04-25 | — | — | US | disclosed |
| US-20160376264-A1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-12-29 | — | — | US | disclosed |
| US-9402840-B2 | Crystalline form of a quinolinone-carboxamide compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-08-02 | — | — | US | disclosed |
| US-9353106-B2 | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-05-31 | — | — | US | disclosed |
| US-20160095849-A1 | CRYSTALLINE FORM OF A QUINOLINONE-CARBOXAMIDE COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-04-07 | — | — | US | disclosed |
| US-20080176895-A1 | Quinolinone-carboxamide compounds as 5-HT4, receptor agonists | ALFASIGMA S.P.A. (IT) | 2008-07-24 | — | — | US | disclosed |
| US-7375114-B2 | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-20070281970-A1 | Quinolinone-Carboxamide Compounds as 5-Ht4 Receptor Agonists | ALFASIGMA S.P.A. (IT) | 2007-12-06 | — | — | US | disclosed |
| US-20070270457-A1 | Quinolinone-carboxamide compounds as 5-HT, receptor agonists | ALFASIGMA S.P.A. (IT) | 2007-11-22 | — | — | US | disclosed |
| US-20070191355-A1 | Process for preparing intermediates to 5-HT4 receptor agonist compounds | THERAVANCE, INC. | 2007-08-16 | — | — | US | disclosed |
| US-20070149662-A1 | coatings comprising water, a film-forming polymer and a leveling agent prepared by reacting glycolic acid with N-glycidyl-N-methylperfluorobutanesulfonamide, used for coating substrates | 3M INNOVATIVE PROPERTIES COMPANY | 2007-06-28 | — | — | US | disclosed |
| EP-1735304-A1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | Theravance, Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20060229332-A1 | crystalline hydrochloride salt of 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[(R)-2-hydroxy-3-(methanesulfonyl-methyl-amino)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide or solvate thereof; treating disease associated with 5-HT4 receptor activity; gastrointestinal tract disorder | THERAVANCE, INC. | 2006-10-12 | — | — | US | disclosed |
| WO-2005100350-A1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| US-20050228014-A1 | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191355-A1 | Process for preparing intermediates to 5-HT4 receptor agonist compounds | HTR4, HTR3B, HTR5A | MEN1 1845/4885KMT2A 1835/4885LMNA 3887/4885 |
| US-20050228014-A1 | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists | HTR4, HTR5A, HTR1A | MEN1 1587/4885KMT2A 1511/4885LMNA 3482/4885 |
| US-20070270457-A1 | Quinolinone-carboxamide compounds as 5-HT, receptor agonists | HTR4, HTR5A, HTR1A | MEN1 1392/4885KMT2A 1436/4885LMNA 3273/4885 |
| US-20160095849-A1 | CRYSTALLINE FORM OF A QUINOLINONE-CARBOXAMIDE COMPOUND | HTR5A, HTR4, HTR2C | MEN1 1675/4885KMT2A 1371/4885LMNA 2512/4885 |
| US-20160376264-A1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR5A, HTR1A | MEN1 1587/4885KMT2A 1511/4885LMNA 3482/4885 |
| US-12275746-B2 | Pyrrolo[1,2-b]-2-pyridazinone compounds as 5-HT4 receptor agonists | HTR4, HTR5A, HTR1B | MEN1 1702/4885KMT2A 3971/4885LMNA 4071/4885 |
| US-20080176895-A1 | Quinolinone-carboxamide compounds as 5-HT4, receptor agonists | HTR4, HTR5A, HTR1A | MEN1 1416/4885KMT2A 1663/4885LMNA 3576/4885 |
| US-20170334901-A1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR5A, HTR1A | MEN1 1587/4885KMT2A 1511/4885LMNA 3482/4885 |
| US-20060229332-A1 | crystalline hydrochloride salt of 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[(R)-2-hydroxy-3-(methanesulfonyl-methyl-amino)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide or solvate thereof; treating disease associated with 5-HT4 receptor activity; gastrointestinal tract disorder | HTR4, HTR5A, HTR2C | MEN1 2376/4885KMT2A 1538/4885LMNA 3608/4885 |
| US-20250019386-A1 | PYRROLO[1,2-b]-2-PYRIDAZINONE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR5A, HTR1B | MEN1 1702/4885KMT2A 3971/4885LMNA 4071/4885 |
| US-20070281970-A1 | Quinolinone-Carboxamide Compounds as 5-Ht4 Receptor Agonists | HTR4, HTR7, HTR3C | MEN1 1341/4885KMT2A 2280/4885LMNA 3889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.